Stockscreener 앱 받기
2.735
1.44%
-0.04
전일 마감가:
$2.775
열려 있는:
$2.705
하루 거래량:
5,550
Relative Volume:
0.34
시가총액:
$6.27M
수익:
$3.19M
순이익/손실:
$-2.23M
주가수익비율:
-2.2248
EPS:
-1.2293
순현금흐름:
$-1.82M
1주 성능:
-1.26%
1개월 성능:
-8.83%
6개월 성능:
+23.98%
1년 성능:
-28.62%
1일 변동 폭
$2.705
$2.74
1주일 범위
$2.6707
$2.9642
52주 변동 폭
$1.90
$13.93
Xenetic Biosciences Inc Stock (XBIO) Company Profile
명칭
Xenetic Biosciences Inc
전화
781-778-7720
주소
945 CONCORD ST., FRAMINGHAM, MA
Compare XBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XBIO
Xenetic Biosciences Inc
|
2.735 | 6.27M | 3.19M | -2.23M | -1.82M | -1.2293 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-01-08 | 개시 | Maxim Group | Buy |
Xenetic Biosciences Inc 주식(XBIO)의 최신 뉴스
Number of shareholders of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Price to book forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Enterprise value to EBITDA forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Price to sales forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Enterprise value to EBIT forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Xenetic Biosciences (XBIO) Surges 6.14% as Stock Tests Key Resistance at $3.09Large Cap Trends - dars.gov.et
XBIOXenetic Biosciences Inc Latest SEC Filings - Finviz
Xenetic Biosciences, Inc. Actuals & Estimates (NASDAQ:XBIO) - TradingView
Xenetic Biosciences Inc (XBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Xenetic Biosciences Inc (XBIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Xenetic Biosciences Inc (XBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Xenetic Biosciences Inc (XBIO) Institutional Confidence - TradingKey
Xenetic Biosciences Inc (XBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Xenetic Biosciences Inc (XBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Xenetic Biosciences Inc (XBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Xenetic Biosciences Inc (XBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Xenetic Biosciences Inc (XBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Xenetic Biosciences (XBIO) Gains 6.7% – Bullish Breakout Within Tight RangeBreakout Stock Alerts - newsline.com
Xenetic Biosciences Inc. (XBIO) Q2 2025 Earnings: Narrowed Loss Beats Expectations, Pipeline Progress KeyOperating Income Trends - dars.gov.et
XBIO Q2 2025 Earnings: EPS Surpasses Estimates Despite No RevenuePre-Earnings Setup - dars.gov.et
XBIO Q2 2025 Earnings: Narrower Loss Beats Estimates, Yet Stock Slips on No Revenue ProgressAnalyst Coverage Count - dars.gov.et
Xenetic Biosciences (XBIO) Secures Approval for Clinical Study i - GuruFocus
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma - ACCESS Newswire
Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates - MSN
Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival - BioSpace
Xenetic presents preclinical data on DNase I with CAR-T therapy - Investing.com Nigeria
Xenetic (XBIO) Reveals Promising Preclinical Results for CAR-T Therapy - GuruFocus
Xenetic presents preclinical data on DNase I with CAR-T therapy By Investing.com - Investing.com South Africa
Xenetic Biosciences, Inc.: Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival - FinanzNachrichten.de
After CAR-T failure, DNase I tied to tumor decline in pediatric lymphoma case - Stock Titan
Michael Liu and MJL Manager LLC report stakes in Xenetic Biosciences (NASDAQ: XBIO) - Stock Titan
XBIO Q2 2025 Earnings: EPS Beat Estimates but Stock Slips on Continued Cash BurnPre-Earnings Drift - newsline.com
Xenetic Biosciences (XBIO) Edges Lower Amid Tight Trading RangeKAMA Signal - dars.gov.et
Xenetic Biosciences (XBIO) Modestly Advances as Biotech Stock Tests Key Resistance ZoneVolume Climax - The Legal Advocate
Xenetic Biosciences Q2 2025 Earnings: Narrowed Loss Exceeds Expectations Amid Oncology Pipeline Progress - The Legal Advocate
Xenetic Biosciences (XBIO) Bounces 3.03%, Holding Above Key SupportBreakout Confirmation - newsline.com
Xenetic Biosciences Q2 2025 Earnings: Narrowed Loss Beats Estimates as Pipeline AdvancesPre-Earnings Drift - Newser
Xenetic Biosciences Shares Edge Down Ahead of ASCO Update - Bez Kabli
XBIO Stock Price, Quote & Chart | XENETIC BIOSCIENCES INC (NASDAQ:XBIO) - ChartMill
Xenetic Biosciences (XBIO) Q2 2025 Earnings Roar: $-0.45 EPS Tops Street ViewCommunity Momentum Stocks - Newser
Xenetic Biosciences (XBIO) Declines -3.75% Amid Market Weakness 2026-05-18Community Watchlist Picks - Newser
Contact Us – Inside INdiana BusinessXenetic Biosciences, Inc.Common Stock (Nasdaq:XBIO) Stock Quote - FinancialContent
TradingKey - TradingKey
Renaissance Holdings Reports 137,440 XBIO Shares (NASDAQ: XBIO) - Stock Titan
Xenetic (XBIO) Reports Strong Q1 Revenue Growth - GuruFocus
Xenetic Virtually Unchanged - Baystreet.ca
Xenetic Biosciences Reports Q1 2026 Results: Advances DNase Oncology Platform, Grows Royalty Revenue, and Strengthens Financial Position - Minichart
Xenetic Biosciences' Q1 royalty revenue rises, net loss narrows - TradingView
Xenetic Biosciences Q1 2026: Royalty Revenue Up 36%, Net Loss Narrows to $0.5M - TradingView
Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform - ACCESS Newswire
Xenetic Biosciences (NASDAQ: XBIO) Q1 2026 results show higher royalties, lower loss - Stock Titan
Xenetic Biosciences Inc (XBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):